If you are having trouble viewing this email, click
here | Sarepta lengthened the duration of the placebo-controlled ESSENCE trial from one year to two. And that’s not making patient advocates happy. |
| The Cambridge drug company has cut two-thirds of its staff in the past two weeks after trial results of its blood cancer drug were said to be disappointing. |
| The deal would nearly double HeartWare’s market value as of Friday. |
| Cambridge-based Syros has proposed an initial public offering of about $60 million. |
| | |
| |
| Cancel Email Subscription You may change your email address, your preferences, or unsubscribe from this email at any time by visiting bizjournals.com: https://www.bizjournals.com/account/ If you need other assistance, please let us know or contact: bizjournals.com customer service, bizjournals 120 W. Morehead St., Charlotte, North Carolina 28202 The Business Journals | Latest News | Advertise | Contact Info | Subscribe to Print Edition © 2016 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of bizjournals. |
